Certolizumab pegol therapy for rheumatoid arthritis-associated scleritis

Cornea

Volumn 31, Issue 1, 2012, Pages 90-91

  Tlucek, Paul S ^a,b   Stone, Donald U ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Certolizumab; Scleritis; Tumor necrosis factor alpha inhibitor

Indexed keywords

CERTOLIZUMAB PEGOL; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOLOGIC FACTOR; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY;

ARTICLE; CASE REPORT; FEMALE; HUMAN; MIDDLE AGED; RHEUMATOID ARTHRITIS; SCLERITIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOLOGIC FACTORS; MIDDLE AGED; POLYETHYLENE GLYCOLS; SCLERITIS; TREATMENT OUTCOME;

EID: 84856505045     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e318211400a     Document Type: Article

References (13)

1. Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am. 2001;27:269-281.
2. Turreson C, O'Fallon WM, Crowson CS, et al. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis. 2003;62:722-727.
3. Bingham CO III. Emerging therapeutics for rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2008;66:210-215.
4. Nam J, Emery P. Aspects of TNF inhibitor therapy in rheumatoid arthritis. Mod Rheumatol. 2010;20:325-330.
5. Keystone E, Heijde D, Mason D Jr, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 2008;58:3319-3329.
6. Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007;13:1323-1332.
7. Ashok D, Ayliffe W, Kiely P. Necrotizing scleritis associated with rheumatoid arthritis: long-term remission with high-dose infliximab therapy. Rheumatology (Oxford). 2005;44:950-951.
8. Restrepo JP, Molina MP. Successful treatment of severe nodular scleritis with adalimumab [published online ahead of print February 14, 2010]. Clin Rheumatol. 2010. Available at: http://www.springerlink.com.webproxy.ouhsc.edu/content/v5230817354712v7/fulltext.pdf. Accessed March 15, 2010.
9. Hernandez-Illas M, Tozman E, Fulcher SF, et al. Recombinant human tumor necrosis factor receptor Fc fusion protein (Etanercept): experience as a therapy for sight-threatening scleritis and sterile corneal ulceration. Eye Contact Lens. 2004;31:2-5.
10. Theodossiadis PG, Markomichelakis NN, Sfikakis PP. Tumor necrosis factor antagonists: preliminary evidence for any emerging approach in the treatment of ocular inflammation. Retina. 2007;27:399-413.
11. Galor A, Perez VL, Hammel JP, et al. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology. 2006;113:2317-2323.
12. Fleischmann R, Vencovsky J, Van Vollenhoven RF, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis. 2009;68:805-811.
13. Smolen J, Landewé RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomized controlled trial. Ann Rheum Dis 2009;68:797-804.